

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KeyMed Biosciences

Keymed Biosciences Inc.

康諾亞生物醫藥科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

STAPOKIBART INJECTION INCLUDED IN THE PRIORITY REVIEW AND APPROVAL PROCEDURES FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, recently, as reviewed by the Center for Drug Evaluation of the National Medical Products Administration (the “**CDE**”), according to the scope of priority review “(I) urgently needed clinical drugs in short supply, innovative drugs and improved new drugs for containment of major infectious diseases and rare diseases”, it has been agreed to include the Stapokibart injection into the priority review and approval procedures for the treatment of chronic rhinosinusitis with nasal polyposis.

About Stapokibart

Stapokibart (R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4R α), and is the first domestically manufactured IL-4R α antibody drug receiving clinical trial approval from the National Medical Products Administration (NMPA). By targeting IL-4R α , Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has shown a good safety profile and encouraging efficacy in a number of previous clinical trials. As of the date of this announcement, the new drug applications of Stapokibart injection for the treatment of moderate-to-severe atopic dermatitis and seasonal allergic rhinitis have been accepted by the National Medical Products Administration.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize Stapokibart successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, May 23, 2024

As at the date of this announcement, the Board of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive directors.